Between the Bells
Tune in to the Bell Direct 'Between the Bells' podcast, where we'll cover the latest economic news and updates, market movements and analysis. With daily updates, you can get the information you need to find your investing edge.
Find Bell Direct here:
Website: https://www.belldirect.com.au/smarter/
Twitter: https://twitter.com/belldirect
Facebook: https://www.facebook.com/BellDirectAustralia
LinkedIn: https://www.linkedin.com/company/bell-direct/
Instagram: https://www.instagram.com/bell.direct/
Between the Bells
From the helm: Amplia Therapeutics (ASX:ATX), CEO & MD, Christopher Burns & Bell Potter Analyst, Thomas Wakim.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this episode of From the Helm, Grady is joined by Amplia Therapeutics (ASX:ATX) CEO & MD Dr Christopher Burns & Bell Potter Analyst Thomas Wakim to unpack the ongoing clinical trials for their prospective treatment drug for pancreatic cancer, and its substantial market opportunities in the US.